首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Serum Erythropoietin Measured by Chemiluminescent Immunometric Assay: An Accurate Diagnostic Test for Absolute Erythrocytosis
【24h】

Serum Erythropoietin Measured by Chemiluminescent Immunometric Assay: An Accurate Diagnostic Test for Absolute Erythrocytosis

机译:化学发光免疫分析法测定血清促红细胞生成素:绝对红细胞增多症的准确诊断测试

获取原文
           

摘要

Absolute erythrocytosis (AE), suspected from a high hemoglobin concentration and/or hematocrit, can be confirmed by an increased red cell mass (RCM) (1). Schematically, one distinguishes three major mechanisms of AE: (a) erythropoietin (Epo)-independent proliferation of clonal erythroid precursors as found in polycythemia vera (PV) and other myeloproliferative disorders; (b) Epo-dependent polyclonal proliferation of erythroid precursors as found in secondary erythrocytoses that are secondary to production of Epo as a consequence of either a physiologic response to tissue hypoxia or of tumoral production; (c) idiopathic erythrocytoses (IEs) in patients without evidence of PV or secondary erythrocytoses (2).The serum Epo concentration reflects its oxygen-regulated production by kidney. Thus, serum Epo is decreased in PV and increased in secondary erythrocytoses. Use of serum Epo as a diagnostic test for PV (3)(4)(5) is controversial(6)(7)(8). Indeed, until recently, the lack of standardization of the reagents and methods impeded identification of reliable thresholds. As a consequence, the diagnosis of PV is still largely based on exclusion and/or indirect clinical and biological criteria initially proposed by the Polycythemia Vera Study Group (PVSG) (9). However, the WHO guidelines (10), which are based on major criteria (e.g., splenomegaly, lack of secondary erythrocytosis) and minor criteria (e.g., modification in blood cell count, bone marrow histology), recently classified the endogenous erythroid colony assay and serum Epo measurements as major and minor PV diagnostic criteria, respectively.We recently demonstrated in a large multicenter study (n = 241) that a commercial ELISA for serum Epo was a reliable and accurate biological diagnostic test in patients with AE (11). In this study, we determined a low Epo threshold with 65% sensitivity and 100% specificity for the diagnosis of PV and a high Epo threshold with 19.7% sensitivity and 100% specificity for secondary erythrocytoses. …
机译:血红蛋白浓度高和/或血细胞比容高可疑的绝对红细胞增多症(AE)可通过增加红细胞质量(RCM)来证实(1)。从原理上讲,一个区分了AE的三种主要机制:(a)在真性红细胞增多症(PV)和其他骨髓增生性疾病中发现,促红细胞生成素(Epo)依赖性的克隆性红系前体的增殖; (b)由于对组织缺氧的生理反应或肿瘤产生而导致的继发于红细胞生成的继发性红细胞增多症中发现的红细胞前体的Epo依赖性多克隆增殖; (c)没有PV或继发性红细胞增多症证据的患者中的特发性红细胞增多症(IEs)(2)。血清Epo浓度反映了肾脏对氧的调节作用。因此,血清Epo的PV降低,继发性红细胞增多。使用血清Epo作为PV(3)(4)(5)的诊断测试是有争议的(6)(7)(8)。的确,直到最近,试剂和方法的缺乏标准化仍阻碍了可靠阈值的鉴定。因此,PV的诊断仍主要基于真性红细胞增多症研究小组(PVSG)最初提出的排除和/或间接临床和生物学标准(9)。但是,WHO指南(10)基于主要标准(例如脾肿大,缺乏继发性红细胞增多症)和次要标准(例如血细胞计数改变,骨髓组织学改变),最近对内源性红系集落测定和血清Epo的测量分别作为主要和次要的PV诊断标准。我们最近在一项大型多中心研究(n = 241)中证明,商业化的血清Epo ELISA是对AE患者的可靠且准确的生物学诊断测试(11)。在这项研究中,我们确定了低Epo阈值对PV的诊断具有65%的敏感性和100%的特异性,而对高Epo阈值对继发性红细胞增多症的敏感性为19.7%并具有100%的特异性。 …

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号